Common inflammatory bowel disease treatment linked to reduced COVID-19 antibody response

(University of Exeter) The findings arose from the CLARITY study, which recruited 6,935 patients with Crohn's disease and ulcerative colitis from 92 UK hospitals between September and December 2020. It found that fewer than half of people with IBD who were treated with infliximab had detectable antibodies after SARS-CoV-2 infection, the coronavirus that causes COVID-19.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news